Theravance Biopharma, Inc. (NASDAQ:TBPH) Stock Now Rated “Hold” by Wall Street Analysts

Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) have been assigned an average recommendation of “Hold” from the eight brokerages that are covering the company, MarketBeat reports. Eight analysts have rated the stock with a hold rating. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $19.40.

A number of analysts have recently issued reports on TBPH shares. HC Wainwright lowered shares of Theravance Biopharma from a “buy” rating to a “neutral” rating and increased their price target for the stock from $15.00 to $17.00 in a research report on Tuesday, July 7th. JonesTrading downgraded shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Monday, June 29th. BTIG Research reiterated a “neutral” rating on shares of Theravance Biopharma in a research note on Thursday, September 24th. Zacks Research downgraded shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Monday, September 7th. Finally, Weiss Ratings upgraded shares of Theravance Biopharma from a “hold (c)” rating to a “hold (c+)” rating in a research report on Monday, August 17th.

Insiders Place Their Bets

In other Theravance Biopharma news, SVP Rhonda Farnum sold 13,314 shares of the company’s stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $17.03, for a total value of $226,737.42. Following the transaction, the senior vice president directly owned 213,476 shares of the company’s stock, valued at $3,635,496.28. This represents a 5.87% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 7.65% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Theravance Biopharma

Several large investors have recently made changes to their positions in TBPH. Dimensional Fund Advisors LP lifted its stake in shares of Theravance Biopharma by 14.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 983,615 shares of the biopharmaceutical company’s stock valued at $15,960,000 after purchasing an additional 124,658 shares during the last quarter. Pacer Advisors Inc. acquired a new position in Theravance Biopharma during the fourth quarter worth $6,342,000. Bank of America Corp DE increased its position in Theravance Biopharma by 78.2% during the first quarter. Bank of America Corp DE now owns 189,155 shares of the biopharmaceutical company’s stock worth $3,070,000 after buying an additional 82,978 shares during the last quarter. Wedge Capital Management L L P NC acquired a new position in Theravance Biopharma during the second quarter worth $2,190,000. Finally, Renaissance Technologies LLC bought a new position in Theravance Biopharma during the first quarter valued at about $2,076,000. Institutional investors own 99.10% of the company’s stock.

Theravance Biopharma Price Performance

TBPH opened at $17.03 on Friday. Theravance Biopharma has a 12-month low of $13.08 and a 12-month high of $21.03. The firm has a market capitalization of $884.18 million, a P/E ratio of 16.86 and a beta of 0.25. The stock has a fifty day moving average of $17.03 and a 200-day moving average of $16.81.

Theravance Biopharma (NASDAQ:TBPH) last announced its quarterly earnings data on Monday, August 10th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.07 by ($0.18). Theravance Biopharma had a negative return on equity of 0.77% and a net margin of 51.58%. The business had revenue of $20.73 million during the quarter, compared to analysts’ expectations of $22.49 million. On average, analysts expect that Theravance Biopharma will post 1.56 earnings per share for the current fiscal year.

About Theravance Biopharma

Theravance Biopharma, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases, with an emphasis on respiratory disorders and other conditions where there is a significant unmet medical need. The company’s research and development activities have historically centered on therapies designed to improve lung function and address chronic respiratory disease.

Its principal marketed product is Yupelri (revefenacin), a once-daily nebulized long-acting muscarinic antagonist for the maintenance treatment of chronic obstructive pulmonary disease (COPD).